RAD17 and cancer: In contrast, the expression of the checkpoint sensors ATR, RAD9, and RAD17 was only modestly increased in cancer samples relative to normal tissues (Fig. 1b), and did not correlate with the downstream components of the pathway (Fig. 1c).